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Genetic polymorphisms in glutathione-S-transferases
are associated with anxiety and mood disorders
in nicotine dependence
Sandra Odebrecht Vargas Nunesa,b, Ma´rcia Regina Pizzo de Castroa,
Maria Angelica Ehara Watanabec, Roberta Losi Guembarovskic,
Heber Odebrecht Vargasa,b, Edna Maria Vissoci Reiched,
Helena Kaminami Morimotod, Seetal Dodde,f,g and Michael Berke,f,g
Background Nicotine dependence is associated with an
increased risk of mood and anxiety disorders and suicide.
The primary hypothesis of this study was to identify
whether the polymorphisms of two glutathione-S-
transferase enzymes (GSTM1 and GSTT1 genes) predict an
increased risk of mood and anxiety disorders in smokers
with nicotine dependence.
Materials and methods Smokers were recruited at the
Centre of Treatment for Smokers. The instruments were
a sociodemographic questionnaire, Fagerstro¨m Test for
Nicotine Dependence, diagnoses of mood disorder and
nicotine dependence according to DSM-IV (SCID-IV),
and the Alcohol, Smoking and Substance Involvement
Screening Test. Anxiety disorder was assessed based on
the treatment report. Laboratory assessment included
glutathione-S-transferases M1 (GSTM1) and T1 (GSTT1),
which were detected by a multiplex-PCR protocol.
Results Compared with individuals who had both GSTM1
and GSTT1 genes, a higher frequency of at least one
deletion of the GSTM1 and GSTT1 genes was identified
in anxious smokers [odds ratio (OR)=2.21, 95%
confidence interval (CI) = 1.05–4.65, P=0.034], but there
was no association with bipolar and unipolar depression
(P=0.943). Compared with nonanxious smokers,
anxious smokers had a greater risk for mood disorders
(OR=4.67; 95% CI=2.24–9.92, P<0.001), lung disease
(OR=6.78, 95% CI=1.95–23.58, P<0.003), and suicide
attempts (OR=17.01, 95% CI=2.23–129.91, P<0.006).
Conclusion This study suggests that at least one deletion
of the GSTM1 and GSTT1 genes represents a risk factor for
anxious smokers. These two genes may modify the
capacity for the detoxification potential against oxidative
stress. Psychiatr Genet 24:87–93 c 2014 Wolters Kluwer
Health | Lippincott Williams & Wilkins.
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Introduction
The relationship between nicotine dependence and
anxiety disorders has been established in epidemiological
and clinical studies. Cigarette smoking is associated with
an increased risk of anxiety disorders. In the National
Comorbidity Survey, nearly 61.3% of individuals with a
lifetime history of panic disorder and 68.4% with
generalized anxiety disorders were current or past
smokers, whereas only 39% of smokers had no mental
disorders (Lasser et al., 2000; Ziedonis et al., 2008).
The nexus between co-occurring disorders such as
smoking, depression, and anxiety is not clear. Depression
and anxiety may increase the risks of smoking, and
smoking may increase the risks of depression and anxiety.
A history of previous psychiatric disorders increases the
risk of early onset of smoking, and contributes to
progression from daily smoking to nicotine dependence
(Breslau et al., 2004). Depression and anxiety symptoms
have been associated with a greater risk for the onset of
smoking behaviors (Patton et al., 1998). In contrast, other
studies have found evidence that smoking increases the
risk for the onset of depression and anxiety disorders
(Pasco et al., 2008; Boden et al., 2010; Moylan et al., 2012).
Smoking appears to increase the risk of the develop-
ment of mood disorders, anxiety disorders, and suicide
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(Pedersen and von Soest, 2009; Berlin et al., 2011).
Nicotine dependence is a vulnerability factor for the
development of severe depressive and anxiety symptoms
and is associated with slower recovery (Jamal et al., 2012).
Previous studies have shown a link between anxiety and
depressive disorders and chronic obstructive pulmonary
disease (COPD); these associations are partly attribut-
able to cigarette smoking and nicotine dependence
(Goodwin et al., 2012). Anxiety and depression are
prevalent comorbidities in COPD and are related to a
worsened course of disease. Genetic variation might also
be an influence in smoking behavior and susceptibility for
diseases induced by tobacco use (Quaak et al., 2009).
It is known that genes coding for the glutathione-S-
transferase M1 (GSTM1) and theta 1 (GSTT1) are
involved in detoxification of many toxic compounds and
products of oxidative stress (Hayes and Pulford, 1995).
Benzo(a)pyrene present in cigarettes is metabolized by
glutathione-S-transferase enzymes. Therefore, glu-
tathione systems protect the cell against xenobiotics
and oxidative and nitrosative stress (Berk et al., 2008).
There are increased oxidative stress damage biomarkers
in mood disorders and nicotine dependences (Nunes
et al., 2013; Vargas et al., 2013a). Glutathione-S-transferase
genes are involved in cellular protection against inflam-
mation and oxidative stress damage from various toxic
substances in tobacco smoke (Kim et al., 2006). A reduced
antioxidant capacity has been described in depressed
smokers (Vargas et al., 2013a).
The absence of GSTM1/GSTT1 activity is the result of
homozygosity for an inherited deletion of these genes,
termed the null genotype (Hayes and Pulford, 1995),
which combined with cigarette smoking has been
implicated as a risk factor for a wide range of tobacco-
related diseases, including susceptibility to coronary heart
disease (Li et al., 2000; Wang et al., 2008; Wang et al., 2010),
cerebrovascular diseases (Um et al., 2006), lung cancer
(Schneider et al., 2004; Lam et al., 2009), and COPD (Xue
et al., 2012). In contrast, another study did not find an
association between GSTM1/GSTT1 null genotype and
risk of ischemic heart disease (Norskov et al., 2011).
In the light of these findings, the current study examines
the role of GSTM1 and GSTT1 genes in smokers with
anxiety and mood disorders. These two genes may modify
the capacity for the detoxification potential against
oxidative stress. We hypothesized that at least one deletion
of the GSTM1 and GSTT1 genes compared with people
who had both GSTM1 and GSTT1 genes is associated with
a greater risk for anxiety and mood disorders in smokers.
Materials and methods
Study population
Smokers (n=151) were recruited from outpatients at the
Centre of Treatment for Smokers, at University Hospital
of Londrina, State University of Londrina (UEL) (Parana´,
Brazil). The controls were never-smokers (n=191) and
were recruited from staff at UEL. This research was
approved by the Ethics Research Committee at State
University of Londrina, and all participants gave written
informed consent to participate in the study. The study
was conducted from March 2011 to July 2012. Smokers
were men and women aged 18–60 years of all ethnicities.
Instruments
Questionnaire
A self-reported questionnaire was used to obtain informa-
tion on smoking status and demographic information.
Clinical characteristics were obtained through an inter-
viewer-administered structured questionnaire.
Nicotine dependence, mood and anxiety disorders
The diagnoses of major depressive disorder, bipolar
disorder, and nicotine dependence were obtained using
the Structured Clinical Interview for DSM-IV, axis I
(SCID-IV) translated and validated into Portuguese
(Del Ben et al., 2001). The diagnosed anxiety disorders
included panic disorder and generalized anxiety disorders
that were reported for ongoing treatment.
Smoking status
The Fagerstro¨m Test for Nicotine Dependence (FTND)
was described by Fagerstro¨m and Schneider (1989). This
instrument was translated and adapted into Portuguese
(Carmo and Pueyo, 2002). The FTND is a self-administered
six-item questionnaire and scores range from 0 to 10.
The number of pack years was calculated according to the
definition: the number of cigarettes smoked per day
number of years smoked/20 (one pack contains 20
cigarettes) (Huxley et al., 2012).
The Alcohol, Smoking and Substance Involvement
Screening Test
The Alcohol, Smoking and Substance Involvement Screen-
ing Test is a questionnaire to screen for risk of alcohol,
smoking, and substance use in adults. Smokers whose
alcohol involvement scores were between 0 and 10 were
considered at low risk, and those with scores between 11
and 26 were at moderate risk of harm and were offered a
brief intervention. Smokers whose sedatives or sleeping
pills scores were between 0 and 3 were at low risk of harm,
and those with scores between 4 and 26 were at moderate
risk of harm and were offered a brief intervention. Smokers
whose score was 27 or more were considered at high risk of
harm and substance dependence and required intensive
intervention (World Health Organization, 2002).
Genotyping
Genomic DNA was extracted from 200 ml of peripheral
blood cells of all participants using the Biopur Kit
(Biometrix Diagnostic, Curitiba, Brazil) according to the
manufacturer’s instructions. After precipitation with
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ethanol, the DNA pellet was resuspended in 50 ml of
Biopur Kit specific buffer, quantified by spectrophoto-
metry, and stored at freezer – 801C for later use in
genotyping analyses.
The genetic polymorphisms were studied using multiplex
PCR protocol (Abdel-Rahman et al., 1996) with modifica-
tions: 80–100 ng of DNA was amplified in a total volume
of 25ml reaction containing 20mmol/l Tris-HCl; 50mmol/l
KCl; 1.5mmol/l MgCl2; 2mmol/l of each deoxynucleotide
triphosphate; 1 pmol of each primer; and 1.25U of
AmpliTaq DNA polymerase. PCR was carried out in a
PTC-100 Termocycler (MJ Research Inc., Minnesota,
USA), after 5min of pretreatment at 941C, 30 cycles of
1min at 941C, 1min at 591C, and 30 s at 721C, followed
by 5min at 721C. The PCR products were analyzed by
electrophoresis on 10% acrylamide gel and detected by
a nonradioisotopic technique using a commercially avail-
able silver staining method.
The genotype was coded according to GSTM1/GSTT1
complete gene deletion polymorphisms: (a) GSTT1
present and GSTM1 absent or GSTT1 absent and
GSTM1 present (at least one gene deleted), (b) both
genes present, and (c) both genes deleted.
The multiplex PCR assay cannot discriminate the
heterozygous presence of the allele from the homozygous
presence. However, the distributions of these two
genotypes were similar to those reported in another
study (Cornelis et al., 2007).
The absence of a 215 bp fragment in the electrophoretic
profile indicates the GSTM1 null genotype, and the
absence of a 480 bp fragment indicates the GSTT1 null
genotype. A fragment of 312 bp related to a nonpoly-
morphic fragment of the CYP1A1 gene was used as an
internal control in all reactions. Negative controls were
analyzed with each experiment.
Statistical analyses
Comparisons were made between smokers with and with-
out anxiety disorders for sociodemographic and clinical
characteristics, and the laboratory measurements, using
appropriate parametric tests where data were normally
distributed and nonparametric statistical tests for cate-
gorical or excluded non-normal data. All associations
between smokers with and without anxiety disorders and
genetic polymorphisms, mood disorders, lung disease, and
suicide attempts were performed using contingency
tables to calculate the odds ratios (OR) and the 95%
confidence interval (CI). All tests were two-tailed and a
P-value of 0.05 was used for statistical significance.
Results
Characteristics of participants
In examining sociodemographic variables, anxious smo-
kers did not differ with respect to marital status, age,
years of education, and ethnicity. There were significantly
more women among the anxious smokers compared with
the nonanxious smokers (P<0.01). Women sought more
treatment for smoking cessation and exhibited higher
rates of anxiety disorders than men. The mean age for all
groups was 46.25 years. There were no significant
differences with respect to years smoked, pack years,
scores on FTND scale, and age of onset of smoking
between anxious and nonanxious smokers (Table 1).
Clinical characteristics
Anxious smokers had significantly more lung disease,
suicide attempts, psychiatric and psychological treat-
ment, use of sedative and sleeping pills, and mood
disorders than nonanxious smokers (P<0.01). There
were no significant differences with respect to diabetes,
hypertension, cardiovascular diseases, alcohol risk, and
BMI (kg/m2) between anxious and nonanxious smokers
(Table 2).
Genotyping
There was a higher frequency of at least one deletion,
compared with the presence of both of the GSTT1 and
the GSTM genes, in anxious smokers (OR=2.21, 95%
CI=1.05–4.65, P=0.034). However, there were no
Table 1 Sociodemographic characteristics of smokers with and
without anxiety disorders
Characteristics
Smokers with anxiety
(n= 96) [n (%)]
Smokers without anxiety
(n= 55) [n (%)]
P-
valuea
Sex 0.002*
Male 26 (27.1) 29 (52.7)
Female 70 (72.9) 26 (47.3)
Age (years) 0.570
18–29 5 (5.2) 5 (9.1)
30–39 11 (11.5) 9 (16.4)
40–49 37 (38.5) 17 (30.9)
50–60 43 (44.8) 24 (43.6)
Ethnicity 0.181
White 62 (64.6) 40 (72.7)
African 13 (13.5) 4 (7.3)
Asian 1 (1.0) 3 (5.5)
Mixed 20 (20.8) 8 (14.5)
Marital status 0.385
Single 15 (15.6) 8 (14.5)
Stable relationship 55 (57.3) 38 (69.1)
Divorced/
separated
20 (20.8) 8 (14.5)
Widow 6 (6.3) 1 (1.8)
Years of education 0.307
r12 67 (72.0) 43 (79.6)
Z13 26 (28.0) 11 (20.4)
Smoking (mean±SD)
Age first smoked 14.8±3.7 15.0±3.4 0.681
Years of smoking 31.9±9.4 31.4±10.3 0.762
Cigarettes/day 22.2±12.9 20.5±10.7 0.383
Pack/year 33.9±21.2 32.6±20.8 0.715
Fagerstro¨m scale 6.0±2.3 5.3±2.0 0.050
Tests are adjusted for all pairwise comparisons within a row using the Bonferroni
correction.
aThe P-value is based on the Pearson w2-test for categorical variables and the
independent sample t-test for the continuous variables.
*Statistically significant difference. In this and subsequent tables P-values should
be interpreted with caution where some cells have values <5.
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significant associations between GSTM1/GSTT1 geno-
types and unipolar and bipolar smokers (P=0.0943)
(Table 3).
The relationship between smoking, mood disorders, lung
disease, suicide attempts, GSTM1/GSTT1 genetic poly-
morphism, and anxiety disorders is shown in Table 4.
The results showed that anxiety disorders were signifi-
cantly associated with mood disorders (OR=4.67, 95%
CI=2.24–9.92, P<0.0001), lung disease (OR=6.78,
95% CI=1.95–23.58, P<0.0026), and suicide attempts
(OR=17.01, 95% CI=2.23–129.91, P<0.006).
Comparisons between the anxious and nonanxious groups
were performed, using pooled smokers and never-smokers
(n=342), to estimate OR with 95% CI and the combined
effects of GST genotypes. There was a positive associa-
tion between anxiety and smokers (OR=4.55, 95%
CI=2.8–7.19, P<0.000), mood disorders (OR=6.32,
95% CI=3.9–10.17, P<0.000), lung disease (OR=3.12,
95% CI=1.61–6.03, P<0.001), and suicide attempts
(OR=18.34, 95% CI=4.26–78.96, P<0.000).
Discussion
Our data confirm results from previous studies in showing
that anxious smokers exhibited having higher rates of
suicide attempts than nonanxious smokers. Smokers who
attempted suicide exhibited 17.0 more likelihood of
having anxiety compared with smokers who did not
attempt suicide. This striking finding is consistent with
the hypothesis that individuals who are nicotine depen-
dent are more likely to be anxious, depressive, and
suicidal (Pedersen and von Soest, 2009; Berlin et al.,
2011). Previous studies have reported that smoking is
associated with a risk of suicidal behavior and depressive
disorders (Malone et al., 2003; Breslau et al., 2005; McGee
et al., 2005; Hughes, 2008; Goodwin et al., 2013). Other
studies have found associations between prior smoking or
nicotine dependence and subsequent suicidal behavior,
which were independent of depression (Boden et al.,
2008; Bronisch et al., 2008).
The smoking and suicide nexus may be explained, in part,
by inflammation and oxidative stress. Individuals with
suicidal behavior had significantly higher levels of nitric
oxide metabolites (products of nitrates and nitrites)
and lipid hydroperoxides (a biomarker of oxidative
damage to lipids or lipid peroxidation) and lower levels
of plasma total antioxidant potential TRAP (a biomarker
Table 2 Clinical characteristics of smokers with and without
anxiety disorders
Clinical characteristics
Smokers
with anxiety
[n (%)]
Smokers
without anxiety
[n (%)] P-value
Suicide attempts 23 (24.0) 1 (1.8) 0.000*
Psychiatric or psychological treatments 48 (50.0) 12 (21.8) 0.001*
Alcohol (ASSIST)a 0.205
Low risk 78 (81.3) 49 (89.1)
Moderate risk 18 (18.8) 6 (10.9)
Sedative and sleeping pills (ASSIST)a 0.013*
Low risk 86 (89.6) 55 (100.0)
Moderate risk 10 (10.4) 0 (0.0)
Mood disorders 0.000*
No depression 37 (38.5) 41 (75.9)
Unipolar depression 25 (26.0) 12 (22.2)
Bipolar depression 34 (35.4) 1 (1.9)
Diabetes 6 (6.3) 4 (7.3) 0.808
Cardiovascular diseases 12 (12.5) 10 (18.2) 0.341
Blood hypertension 33 (34.4) 12 (21.8) 0.105
Lung diseases 27 (28.1) 3 (5.5) 0.001*
BMI > 30 (kg/m2) 30 (31.3) 11 (20.0) 0.149
The P-value tests the association between the clinical characteristics and the two
groups and is based on Pearson w2-test.
ASSIST, Alcohol, Smoking and Substance Involvement Screening Test.
aThere were no ‘high-risk’ participants.
*Statistically significant difference.
Table 3 GSTM1/GSTT1 genetic polymorphism assessments
of smokers with anxiety and mood disorders
Anxiety
and mood
disorder
GSTM1/GSTT1
at least one
deletion (n= 106)
[n (%)]
GSTM1/GSTT1
both genes
present (n= 40)
[n (%)]
OR
(95% CI) P-value
Anxiety 0.034*
Yes 73 (68.9) 20 (50.0) 2.21 (1.05–4.65)
No 33 (31.1) 20 (50.0)
Mood
disorders
0.943
No depression 55 (52.4) 21 (52.5)
Unipolar depression 24 (22.9) 10 (25.0)
Bipolar depression 26 (24.8) 9 (22.5)
CI, confidence interval; GSTM1, glutathione-S-transferases M1 enzyme;
GSTT1, glutathione-S-transferases T1 enzyme; OR, odds ratio.
Table 4 Relationship between smoking, mood disorders, lung
disease, and suicide attempts
Anxiety [n (%)]
Yes No OR 95% CI P-value
Smokers and never-smokers (n= 342)
Smoker
Yes 96 (64.4) 55 (28.5) 4.55 (2.8–7.2) 0.000
No 53 (35.6) 138 (71.5)
Mood disorders
Yes 97 (65.1) 44 (22.8) 6.32 (3.9–10.2) 0.000
No 52 (34.9) 149 (77.2)
Lung disease
Yes 31 (20.8) 15 (7.8) 3.12 (1.6–6.0) 0.001
No 118 (79.2) 178 (92.2)
Suicide attempts
Yes 24 (16.1) 2 (1.0) 18.34 (4.3–79.0) 0.000
No 125 (83.9) 191 (99.0)
Smokers only (n= 151)
Mood disorders
Yes 59 (61.5) 14 (25.5) 4.67 (2.2–9.7) 0.000
No 37 (38.5) 41 (74.5)
Lung disease
Yes 27 (28.1) 3 (5.5) 6.78 (2.0–23.6) 0.003
No 69 (71.9) 52 (94.5)
Suicide attempts
Yes 23 (24.0) 1 (1.8) 17.01 (2.2–129.9) 0.006
No 73 (76.0) 54 (98.2)
CI, confidence interval; OR, odds ratio.
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of total antioxidant defenses) than those without a his-
tory of suicide attempts (Vargas et al., 2013b, in press).
Proinflammatory cytokines have been implicated in
depressive smokers (Nunes et al., 2012). Inflammation
and oxidative stress is a mechanism activating production
of kynurenine, which may deplete tryptophan, leading to
reduced levels of serotonin. Increased plasma kynurenine
levels were found in suicide attempters (Sublette et al.,
2011). Decreased levels of serotonin were related to
suicidal behavior in depressed smokers (Malone et al.,
2003).
Co-occurring affective, anxiety disorders, and nicotine
dependence share pathways that may explain these dis-
orders. First, monoamine oxidases (MAO) catalyze the
metabolism of dopamine, norepinephrine, and serotonin.
Cigarette smoke inhibits the activity of MAO type A and
type B (Benowitz, 2010). Lowered MAO activity, which
may play a role in central nervous system serotonin
metabolism, could modulate, in part, the link between
cigarette smoking and suicidal behavior (Breslau et al.,
2005). Second, this comorbidity can potentially be ex-
plained by one disorder being an epiphenomenon of the
other and by a partly shared genetic etiology (Middeldorp
et al., 2005). Finally, there are alterations of neurotrans-
mitters by inflammation and oxidative stress, and cigarette
smoking and mood disorders are associated with increased
levels of inflammation and oxidative stress (Rytila¨ et al.,
2006; Yanbaeva et al., 2007; Berk et al., 2011; Maes
et al., 2011).
Smokers who had mood disorders exhibited 4.67 times
the risk of having anxiety compared with smokers who did
not have a mood disorder. The relationship between
mood and anxiety disorders was associated with several
markers of clinical severity, including earlier age of onset,
greater number of depressive episodes, and higher
prevalence of attempted suicide, when compared with
mood disorder without comorbid anxiety (Goes et al.,
2012). Comorbidity of anxiety and bipolar/unipolar
disorders, suicidal behavior, substance abuse, and familial
history may be explained by heavy familial-genetic
loading for affective illness (Dilsaver et al., 2006).
Individuals with anxiety and depressive disorders have
increased rates of smoking compared with those without
mental disorders or depression (Lasser et al., 2000).
In the present study, smokers who had lung disease
exhibited 6.78 times the risk of having anxiety compared
with smokers who did not have lung disease. This finding
was consistent with previous studies that have reported
a link between anxiety, depression, and lung disease
(Di Marco et al., 2006; Goodwin et al., 2012). Therefore,
it is necessary to consider the cumulative effects of
depressive and anxiety disorders, physical illnesses, and
smoking on suicide rates. Patients with some pulmonary
diseases have an increased risk of mood and anxiety
disorders (Dome et al., 2010). The association between
lung disease (COPD) and anxiety in smokers may be
accounted for by the higher rate of the null variant of the
enzyme genes in the anxiety group. Because the
association between the polymorphisms and anxiety in
smokers is uncertain it is probably most reasonable to
conjecture that the increased rate of lung disease is due
to the enzyme deficiency rather than to anxiety.
Our study also provides evidence for the association
between at least one deletion of the GSTM1 and GSTT1
genes in anxious smokers, compared with those who had
the presence of both GSTM1 and GSTT1 genes. However,
we did not find significant differences for these
polymorphisms in unipolar and bipolar smokers. These
results are in accordance with another study that did not
find an association of nicotine acetylcholine receptor gene
of smokers with depression, but found that it was
positively associated with the prevalence of both anxious
and depressive smokers (Bjørngaard et al., 2012).
Some limitations of the study need to be mentioned. First,
these results should be confirmed using a larger sample
size. Because of the small sample size, the possibility of
type II statistical errors cannot be excluded. Second, all
participants were recruited from the Centre for Smoking
Cessation. We did not compare smokers with nonsmokers
recruited from the same geographic area and rigorously
matched with the smokers for age and sex of the GSTM1
and GSTT1 genes. However, there were no significant
differences between smokers and nonsmokers for the
GSTM1/GSTT1 gene polymorphisms reported in another
study (Saadat and Mohabatkar, 2004). Third, there is a
considerable overlap between symptoms of anxiety and
mood disorders that needs to be interpreted with caution,
and assessments of anxiety disorders were based on
reported treatment. We did not find differences for mood
disorders; however, further research is needed to clarify this
issue. Finally, this study was conducted on cross-sectional
data, and thus results can only determine associations, not
causality.
A bidirectional relationship might exist between neuro-
transmitter activity, inflammation, and oxidative stress
status in nicotine dependence and depressive disorders
(Nunes et al., 2013). Our data strengthen the hypothesis
of a role of GSTM1 and GSTT1 for the detoxification
potential against oxidative stress in anxious smokers that
exhibited higher rates of suicide attempts and mood
disorders than nonanxious smokers.
Taken all together, the results suggest that both or at least
one deletion of the GSTM1 and GSTT1 genes represent a
risk factor for anxious smokers with co-occurrence with
lung diseases, suicide attempts, sedative use, and mood
disorders. The impact on health risks of this comorbidity
suggests that we need to aggressively target smoking
cessation as a part of routine care (Berk, 2007). Moreover,
it is necessary to develop more effective therapeutic targets
Gene polymorphisms and smoking Vargas Nunes et al. 91
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
to reduce morbidity and mortality due to the co-occurrence
of nicotine dependence and anxiety and mood disorders
and sedative use.
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